Second Quarter 2026
Filed Aug 11, 2026Erasca Reports Second Quarter 2026 Business Updates and Financial Results
The quarter combined updated preliminary ERAS-0015 clinical data, defined upcoming pipeline milestones, and a strengthened cash position following financings, although operating expenses and net loss increased from the prior-year quarter.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expensesGAAP | $35.9 million | – | – |
| General and administrative expensesGAAP | $11.7 million | – | – |
| Net lossGAAP | $44.1 million | – | – |
| Net loss per basic shareGAAP | $(0.14) per basic share | – | – |
| Net loss per diluted shareGAAP | $(0.14) per diluted share | – | – |
| Cash, cash equivalents, and marketable securitiesother | $384.3 million | – | – |
Key Upcoming Milestones outlook
- NoteERAS-0015 Phase 1 monotherapy expansion data expected in the first half of 2027
- NoteERAS-0015 Phase 1 combination dose escalation data, including panitumumab combination, expected in the first half of 2027
- NotePotentially registration-enabling trial in 2L+ NSCLC expected to initiate in the first half of 2027
- NotePhase 3 pivotal trial in 1L PDAC expected to initiate in 2027
- NotePhase 3 pivotal trial in RASm NSCLC expected to initiate in the second half of 2027 to the first half of 2028
- NoteERAS-4001 preliminary Phase 1 monotherapy data expected in the second half of 2026
- NoteInitiation of ERAS-4001 monotherapy expansion cohorts and combination dose escalation cohorts planned for 2027
- NoteErasca expects its current cash, cash equivalents, and marketable securities (inclusive of the net proceeds received from the July 2026 underwritten offering) will be sufficient to fund the Key Upcoming Milestones set forth above in this press release.
What drove it
- At the recommended dose for expansion of 32 mg once daily, ERAS-0015 demonstrated a 57% uORR 8wk in 2L+ KRAS G12X PDAC, with ongoing treatment across all responding patients and most enrolled patients.
- ERAS-0015 reported mostly low-grade treatment-related adverse events, no dose-limiting toxicities, no treatment-related discontinuations, and a median relative dose intensity of 100% at both the 24 mg QD and 32 mg QD RDEs.
- The company cleared the first 16 mg dose-escalation cohort of ERAS-0015 in combination with panitumumab after demonstrating no DLTs; backfill enrollment is ongoing in the 16 mg combination cohort and dose escalation is continuing in the 24 mg combination cohort.
- R&D expense increased primarily due to clinical trials, preclinical studies, discovery activities, outsourced services, consulting fees, and personnel costs, including stock-based compensation expense.
- G&A expense increased primarily due to personnel costs, including stock-based compensation expense, and legal costs.
Concerns
- Net loss was $44.1 million for the quarter ended June 30, 2026, compared to $33.9 million for the quarter ended June 30, 2025.
- R&D expenses were $35.9 million for the quarter ended June 30, 2026, compared to $21.2 million for the quarter ended June 30, 2025.
- The company stated that interim, topline and preliminary clinical-trial results are not necessarily indicative of final results and may materially change as enrollment and follow-up continue.
- Potentially registration-enabling trials may be delayed based on FDA feedback or requirements, and successful planned trials may not support regulatory approval.
What to watch
- ERAS-4001 preliminary Phase 1 monotherapy data expected in the second half of 2026.
- ERAS-0015 Phase 1 monotherapy expansion data expected in the first half of 2027.
- ERAS-0015 Phase 1 combination dose escalation data, including the panitumumab combination, expected in the first half of 2027.
- Potential initiation of the ERAS-0015 2L+ NSCLC potentially registration-enabling trial in the first half of 2027.
- Phase 3 pivotal trial initiation plans for 1L PDAC in 2027 and RASm NSCLC in the second half of 2027 to the first half of 2028.
- Use of the July 2026 underwritten-offering net proceeds and the company's stated ability to fund the listed upcoming milestones.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities were $384.3 million as of June 30, 2026, compared to $341.8 million as of December 31, 2025.
- In July 2026, Erasca completed an upsized public offering, raising approximately $632.5 million in gross proceeds.
- Erasca's January 2026 upsized public offering raised approximately $258.8 million in gross proceeds.
Analysis
Erasca's second-quarter update centered on clinical progress rather than commercial performance. ERAS-0015 produced a 57% uORR 8wk at the 32 mg once-daily recommended dose for expansion in 2L+ KRAS G12X PDAC. The company also reported ongoing treatment across all responding patients and most enrolled patients, alongside mostly low-grade treatment-related adverse events, no dose-limiting toxicities, no treatment-related discontinuations, and a median relative dose intensity of 100% at the 24 mg QD and 32 mg QD RDEs.
The development plan broadened during July. The company cleared the first 16 mg ERAS-0015 plus panitumumab dose-escalation cohort with no DLTs, is enrolling a backfill cohort at that dose, and is continuing escalation in the 24 mg combination cohort. Management identified ERAS-0015 monotherapy and combination data in the first half of 2027 as key next disclosures, while ERAS-4001 preliminary Phase 1 monotherapy data are expected in the second half of 2026.
Expenses and loss increased from the comparable prior-year period. R&D expenses were $35.9 million versus $21.2 million, driven by clinical trials, preclinical studies, discovery activities, outsourced services, consulting fees, and personnel costs. G&A expenses were $11.7 million versus $9.5 million. Net loss was $44.1 million, or $(0.14) per basic and diluted share, compared with $33.9 million, or $(0.12) per basic and diluted share. The release does not provide prior-quarter operating results, so quarter-over-quarter changes cannot be assessed from the filing.
Liquidity strengthened through financing activity. Cash, cash equivalents, and marketable securities were $384.3 million as of June 30, 2026, compared with $341.8 million as of December 31, 2025. Erasca subsequently completed an upsized public offering in July that raised approximately $632.5 million in gross proceeds, following an approximately $258.8 million gross-proceeds offering in January. The company stated that current cash, cash equivalents, and marketable securities, inclusive of net July offering proceeds, will be sufficient to fund the listed upcoming milestones.
The central execution issues are conversion of preliminary ERAS-0015 activity into subsequent data sets and progress toward the planned potentially registration-enabling programs in NSCLC, PDAC, and RASm NSCLC. The company explicitly notes that preliminary results may change with additional enrollment and follow-up, and that FDA feedback or requirements could delay planned potentially registration-enabling trials or require additional data.
Management, verbatim
Updated clinical data from our U.S. trial further bolster our excitement for advancing ERAS-0015, with compelling monotherapy activity in 2L+ KRAS G12X pancreatic cancer, previously disclosed encouraging data in 2L+ KRAS G12X lung cancer, sustained tolerability with longer follow-up, and promising combination potential.
Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder
Not in the filing
stated, not guessed- Total revenue
- Revenue by segment
- Gross profit and gross margin
- Operating income or loss
- Non-GAAP financial measures, including non-GAAP operating income, net income or loss, and EPS
- Operating cash flow
- Free cash flow
- Debt balance
- Dividend payments
- Share repurchases
- Tax rate
- Detailed cash-flow statement items
- Prior-quarter R&D expenses, G&A expenses, net loss, and EPS
- Percentage year-over-year and quarter-over-quarter changes for reported financial metrics
- Financial guidance for revenue, gross margin, operating expenses, or tax rate
- Previous-quarter outlook for comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.